150 related articles for article (PubMed ID: 10548309)
1. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti.
Jirakanjanakit N; Khin MM; Yoksan S; Bhamarapravati N
Am J Trop Med Hyg; 1999 Oct; 61(4):672-6. PubMed ID: 10548309
[TBL] [Abstract][Full Text] [Related]
2. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.
Troyer JM; Hanley KA; Whitehead SS; Strickman D; Karron RA; Durbin AP; Murphy BR
Am J Trop Med Hyg; 2001 Nov; 65(5):414-9. PubMed ID: 11716092
[TBL] [Abstract][Full Text] [Related]
3. Dengue-2 vaccine: oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti.
Miller BR; Beaty BJ; Aitken TH; Eckels KH; Russell PK
Am J Trop Med Hyg; 1982 Nov; 31(6):1232-7. PubMed ID: 7149108
[TBL] [Abstract][Full Text] [Related]
4. Dengue-2 vaccine: infection of Aedes aegypti mosquitoes by feeding on viremic recipients.
Bancroft WH; Scott RM; Brandt WE; McCown JM; Eckels KH; Hayes DE; Gould DJ; Russell PK
Am J Trop Med Hyg; 1982 Nov; 31(6):1229-31. PubMed ID: 7149107
[TBL] [Abstract][Full Text] [Related]
5. Dengue 3 virus infection of Aedes albopictus and Aedes aegypti: comparison of parent and progeny candidate vaccine viruses.
Schoepp RJ; Beaty BJ; Eckels KH
Am J Trop Med Hyg; 1990 Jan; 42(1):89-96. PubMed ID: 2301711
[TBL] [Abstract][Full Text] [Related]
6. Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.
Hanley KA; Goddard LB; Gilmore LE; Scott TW; Speicher J; Murphy BR; Pletnev AG
Vector Borne Zoonotic Dis; 2005; 5(1):1-10. PubMed ID: 15815144
[TBL] [Abstract][Full Text] [Related]
7. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation.
Schoepp RJ; Beaty BJ; Eckels KH
Am J Trop Med Hyg; 1991 Aug; 45(2):202-10. PubMed ID: 1877715
[TBL] [Abstract][Full Text] [Related]
8. The use of Toxorhynchites splendens for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine.
Jirakanjanakit N; Khin MM; Yoksan S; Bhamarapravati N
Vaccine; 1999 Feb; 17(6):597-601. PubMed ID: 10075167
[TBL] [Abstract][Full Text] [Related]
9. Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by
Dietrich EA; Ong YT; Stovall JL; Dean H; Huang CY
Am J Trop Med Hyg; 2017 Nov; 97(5):1423-1427. PubMed ID: 28820715
[TBL] [Abstract][Full Text] [Related]
10. Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.
Sardelis MR; Edelman R; Klein TA; Innis BL; Putnak JR; Jones JW; Turell MJ
Am J Trop Med Hyg; 2000 Jun; 62(6):698-701. PubMed ID: 11304057
[TBL] [Abstract][Full Text] [Related]
11. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
12. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti.
Khin MM; Jirakanjanakit N; Yoksan S; Bhamarapravati N
Am J Trop Med Hyg; 1994 Dec; 51(6):864-9. PubMed ID: 7810824
[TBL] [Abstract][Full Text] [Related]
13. Vector competence of the Aedes aegypti population from Santiago Island, Cape Verde, to different serotypes of dengue virus.
da Moura AJ; de Melo Santos MA; Oliveira CM; Guedes DR; de Carvalho-Leandro D; da Cruz Brito ML; Rocha HD; Gómez LF; Ayres CF
Parasit Vectors; 2015 Feb; 8():114. PubMed ID: 25888847
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
[TBL] [Abstract][Full Text] [Related]
15. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.
Higgs S; Vanlandingham DL; Klingler KA; McElroy KL; McGee CE; Harrington L; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2006 Nov; 75(5):986-93. PubMed ID: 17124001
[TBL] [Abstract][Full Text] [Related]
16. Effect of anticoagulants on the susceptibility of Aedes aegypti mosquitoes to dengue virus infection.
Mourya DT
Acta Virol; 2002; 46(1):51-3. PubMed ID: 12197636
[No Abstract] [Full Text] [Related]
17. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
[TBL] [Abstract][Full Text] [Related]
18. Vector competence of Aedes albopictus and Aedes aegypti (Diptera: Culicidae) for the DEN2-FJ10 and DEN2-FJ11 strains of the dengue 2 virus in Fujian, China.
Guo XX; Li CX; Zhang YM; Xing D; Dong YD; Zhang HD; Qin CF; Zhao TY
Acta Trop; 2016 Sep; 161():86-90. PubMed ID: 27260668
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.
Velzing J; Groen J; Drouet MT; van Amerongen G; Copra C; Osterhaus AD; Deubel V
Vaccine; 1999 Mar; 17(11-12):1312-20. PubMed ID: 10195766
[TBL] [Abstract][Full Text] [Related]
20. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.
McGee CE; Tsetsarkin K; Vanlandingham DL; McElroy KL; Lang J; Guy B; Decelle T; Higgs S
J Infect Dis; 2008 Mar; 197(5):686-92. PubMed ID: 18266608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
